GleamWall
中文EN

URGN UroGen Pharma Ltd.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1668243 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY159.3%
TTM net income YoY60.1%
TTM EPS YoY—
Revenue 3-yr CAGR47.9%
Net income 3-yr CAGR—

Margins

Gross margin91.4%
Operating margin-12.4%
Net margin-26.3%
FCF margin-52.8%
EBITDA margin-12.2%

Returns

ROE—
ROA-28.8%
ROIC (approx.)—
Asset turnover1.10x

Leverage & solvency

Liabilities / assets146.1%
Debt / equity—
Current ratio3.40x
Interest coverage—

Cash quality & payout

Operating cash flow / net income2.01x
Accruals ratio28.9%
Payout ratio—
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q42024-12-31
Income statement
Revenue$89.00M$72.46M$50.96M$37.84M$27.48M$24.21M$20.25M$24.57M
Cost of revenue$7.50M$6.57M$4.14M$3.29M$3.28M$3.55M$2.33M$2.47M
Gross profit$81.50M$65.88M$46.82M$34.55M$24.20M$20.66M$17.92M$22.09M
R&D expense$25.96M$17.34M$15.60M$14.31M$14.01M$18.91M$19.87M$14.89M
SG&A expense$47.21M$48.44M$51.49M$39.35M$37.58M$43.20M$34.97M$34.86M
Operating income$8.33M$111,000-$20.26M-$19.11M-$27.39M-$41.45M-$36.91M-$27.66M
Pretax income-$446,000-$8.72M-$28.35M-$26.64M-$34.40M-$48.92M-$43.45M-$34.86M
Income tax$1.02M$5.63M-$4.77M-$275,000-$1.05M$1.01M$392,000$2.65M
Net income-$1.46M-$14.35M-$23.57M-$26.36M-$33.35M-$49.94M-$43.84M-$37.51M
EBITDA$8.43M$211,000-$20.19M-$19.04M-$27.29M-$41.35M-$36.84M-$27.59M
EPS (basic)-0.03-0.28-0.47—-0.69-1.05-0.92-0.80
EPS (diluted)————————
Balance sheet
Cash & equivalents$85.56M$79.13M$109.97M$110.75M$90.04M$92.90M$104.03M$171.99M
Short-term investments$6.35M$30.16M$39.74M$9.71M$63.79M$83.11M$112.03M$110.67M
Receivables$117.28M$88.76M$55.41M$33.08M$19.70M$19.65M$19.64M$20.30M
Inventory$25.15M$24.59M$20.92M$16.46M$8.34M$7.13M$7.59M$9.23M
Current assets$251.90M$235.43M$237.46M$186.02M$168.55M$196.87M$237.18M$276.13M
PP&E, net$588,000$597,000$616,000$637,000$695,000$688,000$627,000$655,000
Total assets$271.87M$252.59M$253.69M$200.46M$185.05M$208.72M$247.62M$285.71M
Current liabilities$74.03M$61.91M$50.63M$46.42M$42.24M$47.55M$42.00M$45.95M
Long-term debt$189.35M$188.73M$189.53M$122.21M$122.11M$122.51M$122.11M$121.73M
Total debt$189.35M$188.73M$189.53M$122.21M$122.11M$122.51M$122.11M$121.73M
Total liabilities$397.09M$384.99M$377.94M$305.93M$300.45M$302.09M$294.08M$294.51M
Shareholders' equity-$125.22M-$132.40M-$124.25M-$105.47M-$115.41M-$93.38M-$46.46M-$8.80M
Net debt$103.79M$109.60M$79.56M$11.46M$32.07M$29.60M$18.07M-$50.25M
Shares outstanding49.03M48.87M48.71M48.35M46.78M46.20M46.10M42.23M
Cash flow statement
Operating cash flow-$15.20M-$33.01M-$45.32M-$38.33M-$42.27M-$39.83M-$42.02M-$13.62M
Capital expenditure$72,000$60,000$54,000$17,000$87,000$141,000$44,000$115,000
Free cash flow-$15.27M-$33.07M-$45.37M-$38.34M-$42.36M-$39.97M-$42.07M-$13.73M
Investing cash flow$19.85M$1.67M-$20.69M$27.72M$31.40M$28.41M-$25.96M$60.62M
Financing cash flow$1.78M$500,000$65.20M$31.32M$8.27M$296,000$34,000$71,000
Depreciation & amortization$100,000$100,000$75,000$75,000$100,000$100,000$72,000$68,000
Stock-based compensation$6.25M$5.33M$4.63M$3.13M$3.03M$2.73M$3.07M$3.30M

Free plan shows the latest 8 periods; Pro shows all 39 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.